Profile of presentation of HIV-positive patients to an emergency department in Johannesburg, South Africa

Background: Despite improved availability and better access to antiretroviral therapy (ART), approximately 36% of human immunodeficiency virus (HIV)-positive South Africans are still not virally suppressed.

Objective: The aim of this study was to describe the patterns of presentation of HIV-positive patients to a major central hospital emergency department (ED).

Methods: In this prospectively designed study, consecutive HIV-positive patients presenting to the Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) adult ED were enrolled between 07 July 2017 and 18 October 2018.

Results: A total of 1224 participants were enrolled. Human immunodeficiency virus was newly diagnosed in 212 (17.3%) patients, 761 (61.2%) were on ART, 245 (32.2%) reported ART non-adherence, 276 (22.5%) had bacterial pneumonia, 244 (19.9%) had tuberculosis (TB), 205 (16.7%) required intensive care unit admission, 381 (31.1%) were admitted for ≥ 7 days and 166 (13.6%) died. With regard to laboratory parameters, CD4 cell count was < 100 cell/mm3 in 527 (47.6%) patients, the viral load (VL) was > 1000 copies/mL in 619 (59.0%), haemoglobin was < 11 g/dL in 636 (56.3%), creatinine was > 120 μmol/L in 294 (29.3%), lactate was > 2 mmol/L in 470 (42.0%) and albumin was < 35 g/L in 633 (60.8%).

Conclusion: Human immunodeficiency virus-positive patients presenting to the CMJAH ED demonstrated a high prevalence of opportunistic infections, required a prolonged hospital stay and had high mortality rates. There is a need to improve the quality of ART services and accessibility to care.

Keywords: HIV; emergency department; ART non-adherence; CD4 cell count; HIV viral load; opportunistic infections; hospital admission; mortality.

Introduction

Human immunodeficiency virus (HIV) infection is an epidemic, which has affected approximately 38 million people worldwide. In 2019, 1.7 million new infections and 690 000 HIV-related deaths were recorded.1 Two-thirds of the global population of persons living with HIV (PLWH) are in sub-Saharan Africa (SSA). South Africa (SA) contributes approximately 7.5 million to the global number, that is, more than twice that of any other country worldwide.2

The availability of antiretroviral therapy (ART) globally has reduced HIV-associated morbidity and mortality rates.3-4 Indeed, the life expectancy of PLWH in some regions is now comparable to that of the general population.5 Although there has been a significant increase in the global number of PLWH on ART in recent years,6 the burden of HIV-related illness is still substantial,7 especially amongst those who are newly diagnosed, ART-naive and those who were recently initiated on ART.8 Other factors contributing to poor HIV-related outcomes include non-adherence to ART, treatment resistance and severe immune deficiency (low CD4 cell counts) at the time of presentation.9 Furthermore, loss to follow-up (LTFU) remains a problem despite growth in the numbers starting on ART.4,10

Emergency departments (EDs) are frequently the first ‘port-of-call’ for PLWH who experience an acute deterioration in health. Despite free access to ART in SA’s public health system,11 recent

Copyright: © 2021. The Authors. Licensee: AOSIS. This work is licensed under the Creative Commons Attribution License.
data confirm that approximately 30% of eligible persons are not yet on ART, and of those on ART, 36% are not virally suppressed. Although these figures have improved since the inception of the ART roll-out in 2004, admission with acute HIV-related illness is still high. These figures fall short of the 2020/30 Joint United Nations Programme on HIV and AIDS (UNAIDS) 90-90-90 targets. The country’s healthcare service and in particular it’s EDs depict an early barometer of progress in achieving these goals.

In this study, we describe the profile of presentation of acutely ill PLWH to the ED of a large tertiary hospital. We also describe demographic characteristics, HIV-related history, vital signs, routine laboratory parameters, presenting diagnosis, patient disposition and outcomes.

Methods

This study was conducted in the adult medical-ED of the Charlotte Maxeke Johannesburg Academic Hospital (CMJAH), a 1088-bed tertiary-level academic hospital affiliated to the University of the Witwatersrand. The adult medical ED manages all non-trauma patients who, on arrival, are triaged as ‘emergent’ (red), ‘very urgent’ (orange), ‘urgent’ (yellow) and ‘routine’ (green) based on specific criteria as defined by the SA Triage Scale. In general, patients who are triaged as ‘routine’ (green) are referred to a lower-level facility for further management. In addition, patients not residing within the drainage area of the CMJAH, and who are transportation stable, are referred to an appropriate facility closer to the patient’s residence.

Before the commencement of data collection, informal training pertaining to the methodology and principles of data collection from medical charts was undertaken by the primary investigator. Furthermore, all doctors employed in the ED were briefed regarding the aims, objectives and design of the study. Doctors were thereafter requested to inform the primary investigator of all HIV-positive patients managed in the ED. Written informed consent for study participation was obtained by the primary investigator or the doctor on shift. If participants were unable to grant consent (e.g. decreased level of consciousness), consent was obtained from the next of kin/legal guardian and later re-obtained from the participant after his or her mental condition had improved. Human immunodeficiency virus-negative patients, HIV-unknown patients not consenting to HIV testing and patients not consenting to participate in the study were excluded from the study. Emergency department registers were also reviewed daily in an effort to identify potential participants who were missed by the ED doctors.

The four-question AIDS Clinical Trials Group Adherence Questionnaire (ACTG-AQ) was used in order to determine non-adherence to ART. The questionnaire was administered to all participants prescribed ART at any time in the past.

Data were extracted from the patient’s hospital records by the primary investigator and entered into an anonymised and standardised data collection form. Additional information relevant to the study but not found in the patient’s hospital records was directly obtained from the participant, the participant’s laboratory records or the participant’s next of kin/legal guardian where applicable.

Only where the next of kin/legal guardian indicated that they were aware of the participant’s HIV status, they were questioned regarding relevant HIV-history such as treatment adherence. Data from hospital records were recorded daily for the entire duration of hospital stay until data collection was completed. Inter-rater reliability was assessed by an independent researcher experienced in the methods of data collection and blinded to the study aims and objectives. Data extracted from a random sample of 43 medical charts were compared with those extracted by the primary investigator.

Data relevant to this study included demographic details, HIV status, prior ART history including non-adherence, vital signs including the Glasgow Coma Scale (GCS) score, respiratory rate, systolic blood pressure, oxygen saturation, heart rate and temperature, baseline laboratory findings at the time of the current presentation including CD4 cell count, HIV viral load (VL), haemoglobin, white cell count, platelet count, urea, creatinine, albumin, lactate, C-reactive protein (CRP) and alanine transaminase (ALT), presenting diagnosis, number of organ systems affected at presentation, disposition from the ED, length of hospital stay and in-hospital mortality. The vital signs data were used to calculate the quick Sequential Organ Failure Assessment (qSOFA) score and the National Early Warning Score 2 (NEWS-2). Both qSOFA and NEWS-2 are standardised scoring tools that characterise acute illness severity, with higher scores indicating greater severity of illness and a higher risk for worse outcomes. The various presenting diagnoses were either microbiologically or histologically confirmed or were deemed as the most likely diagnosis based on clinical assessment, special investigations and after discussion with relevant sub-speciality clinicians. Data were thereafter exported to Microsoft Excel (Microsoft 365, Version 16.0.13029.20232) and analysed and described using either the median and standard deviation or frequency and percentages.

Ethical consideration

Data collection commenced once ethical approval from the University of the Witwatersrand Human Research Ethics Committee (clearance certificate number: M160512) and relevant permissions were obtained. Adult patients (≥ 18 years) known to be living with HIV, including those newly diagnosed, were prospectively enrolled into the study between 07 July 2017 and 18 October 2018. As per the CMJAH ED protocol, besides patients that are already HIV-positive (either self-reported or confirmed on laboratory records of patients that previously attended the facility), all other patients attending the ED are offered HIV-rapid diagnostic testing to determine their HIV status. As per the National Department of Health (NDoH) protocol, and after obtaining
consent, two different HIV-rapid diagnostic tests were performed where the HIV status was unknown. Blood was initially tested with the Abon HIV 1/2/0 Tri-line Rapid test (Abon Biopharm, Hangzhou, RR China). Reactive samples were subjected to a second confirmatory rapid test, namely, the First Response HIV 1–2.0 card (PMC Medical India Pvt, Lt, Daman, India). Patients testing positive with both, that is, newly diagnosed as HIV-positive, were also approached for study consent and participation. For patients in whom the first test was positive but the second test was negative, whole blood was drawn and sent to the laboratory for an enzyme-linked immunosorbent assay (ELISA) HIV-test. These were only approached for study participation if the confirmatory test was positive.

Results

During the data collection period, 29 416 patients presented to the adult medical ED triage area, of which 11 383 were triaged into the ED for further management. The remaining patients were referred to an appropriate facility in accordance with the CMJAH ED triage protocol. A total of 1012 patients were HIV-positive, of which 84 were excluded from the study as informed consent could not be obtained. A total of 1224 participants were included in the final study sample.

Table 1 describes the median (IQR) age of study participants. The median (IQR) age of the entire cohort was 36 (IQR 31–44) years, with the median (IQR) age of men being older than that of women. Other demographic characteristics, new diagnosis with HIV, ART initiation and adherence, vital signs and laboratory findings of study participants are presented in Table 2. Most participants were women (n = 673, 97.6%), black (n = 1174, 95.9%), single (n = 937, 76.6%) and had completed secondary school as the highest level of education (n = 1195, 97.6%). Those who were not South African nationals comprised a fifth (n = 253, 20.7%) of study participants.

Approximately one-sixth of participants (n = 212, 17.3%) were newly diagnosed with HIV at presentation. Of the 1012 participants who were diagnosed with HIV prior to ED presentation, 761 (75.2%) were on ART. Of these, 245 (32.2%) were non-adherent as per the ACTG-AQ self-report questionnaire. Respiratory rate was > 20 breaths/min in 434 (38.8%) participants, oxygen saturation was < 90% in 196 (17.5%), systolic blood pressure was < 90 millimetre of mercury (mmHg) in 116 (10.4%), heart rate was > 110 beats/min in 565 (50.6%) and GCS was < 15 in 221 (19.2%) participants.

The overall median CD4 cell count and HIV VL were 112 (IQR, 34–295) cell/cubic millimetre (mm3) and 8815

| Variable | Entire cohort | Male | Female |
|----------|--------------|------|--------|
| Median age (years) (IQR) | 36 (31–44) | 38 (32–45) | 35 (30–43) |

TABLE 1: Description of the median (interquartile range) age of study participants.

HIV diagnosis and ART initiation/adherence

Table 2. Description of demographic characteristics, human immunodeficiency virus diagnosis, antiretroviral therapy initiation and adherence, vital signs and laboratory findings of study participants.

| Variable | n | % |
|----------|---|---|
| **Demographic characteristics** | | |
| Sex | | |
| Female | 673/1224 | 55.0 |
| Male | 551/1224 | 45.0 |
| Race | | |
| Black | 1174/1224 | 95.9 |
| Other† | 50/1224 | 4.1 |
| Marital status | | |
| Single | 937/1224 | 76.6 |
| Married | 287/1224 | 23.4 |
| Highest level of education | | |
| Secondary school | 1195/1224 | 97.6 |
| Primary school | 16/1224 | 1.3 |
| Tertiary education | 13/1224 | 1.1 |
| Nationality | | |
| South African | 971/1224 | 79.3 |
| Non-South African | 253/1224 | 20.7 |
| **HIV diagnosis and ART initiation/adherence** | | |
| Newly diagnosed with HIV | 212/1224 | 17.3 |
| ART initiated prior to ED presentation‡ | 761/1012 | 75.2 |
| ART non-adherence | 245/761 | 32.2 |
| **Vital signs** | | |
| Respiratory rate > 20 breaths/min | 434/1118 | 38.8 |
| Oxygen saturation < 90% | 196/1117 | 17.5 |
| Systolic blood pressure < 90 mmHg | 116/1117 | 10.4 |
| Heart rate > 110 beats/min | 565/1117 | 50.6 |
| **Glasgow coma scale** | | |
| 15 | 929/1150 | 80.8 |
| 12–14 | 176/1150 | 15.3 |
| 9–11 | 38/1150 | 3.3 |
| < 9 | 7/1150 | 0.6 |
| **Laboratory findings** | | |
| CD4 < 100 cell/mm³ | 527/1105 | 47.6 |
| HIV viral load > 1000 copies/mL | 619/1049 | 59.0 |
| Haemoglobin | | |
| > 10.9 g/dL | 550/1129 | 48.7 |
| 8–10.9 g/dL | 366/1129 | 32.4 |
| < 8 g/dL | 213/1129 | 18.9 |
| White cell count < 4.0 × 10⁹/L | 170/1127 | 15.1 |
| Platelet count < 150 × 10⁹/L | 223/1121 | 19.9 |
| Urea > 10 mmol/L | 277/1069 | 25.9 |
| Creatinine | | |
| ≤ 120 μmol/L | 761/1061 | 71.7 |
| 121–200 μmol/L | 129/1061 | 12.2 |
| > 200 μmol/L | 171/1061 | 16.1 |
| C-reactive protein | | |
| ≤ 10 mg/L | 164/1059 | 15.5 |
| 11–50 mg/L | 193/1059 | 18.2 |
| 51–100 mg/L | 186/1059 | 17.6 |
| > 100 mg/L | 516/1059 | 48.7 |
| Lactate | | |
| ≤ 2.0 mmol/L | 648/1118 | 58.0 |
| 2.1–5.0 mmol/L | 387/1118 | 34.6 |
| > 5.0 mmol/L | 83/1118 | 7.4 |
| Albumin | | |
| > 34 g/L | 408/1042 | 39.1 |
| 25–34 g/L | 426/1042 | 40.9 |
| < 25 g/L | 208/1042 | 20.0 |
| Alanine transaminase > 100 mmol/L | 109/1029 | 10.6 |

Note: The denominator has been included for all variables to account for missing data.

† Includes Asian, Caucasian and mixed race.

‡ Percentage calculated amongst participants who were known with HIV prior to ED presentation.
(37–325 898) copies/millilitre (mL), respectively. Almost half of the study participants \((n = 527, 47.6\%)\) had a CD\(_4\) cell count of < 100 cell/mm\(^3\), whilst more than half \((n = 619, 59.0\%)\) had a VL of > 1000 copies/mL. Amongst participants on ART who reported non-adherence, the HIV VL was > 1000 copies/mL in more than two-thirds of participants \((n = 167, 68.2\%)\).

More than half of the participants \((n = 579, 51.3\%)\) presented with varying degrees of anaemia (haemoglobin < 11 grams per decilitre [g/dL]), whilst creatinine was > 120 micromole per litre (μmol/L) in 291 (23.8%), CRP was > 10 millimoles per litre (mmol/L) in 895 (74.5%), lactate was > 2 mmol/L in 470 (42.0%) and albumin was < 35 g/L in 634 (60.8%) participants.

Approximately one-fifth of participants \((n = 244, 19.9\%)\) presented with active tuberculosis (TB), of whom 70 (28.7%) had disseminated TB, whilst 143 (58.6%) had extrapulmonary TB (EPTB). The median CD\(_4\) cell count was higher, and the median HIV VL was lower amongst participants with (1) a recurrent episode of TB compared with those with a first episode, (2) TB of a single organ compared with those with disseminated TB and (3) isolated pulmonary TB (PTB) compared with those with EPTB. These and other findings pertaining to TB amongst study participants are presented in Table 3.

Table 4 describes the most frequent presenting diagnoses amongst study participants and the corresponding median (IQR) CD\(_4\) cell count and HIV VL. Most participants presented with respiratory system pathology \((n = 533, 43.5\%)\), followed by pathology involving the genitourinary system \((n = 249, 20.3\%)\), gastrointestinal system \((n = 223, 18.2\%)\) and central nervous system \((n = 145, 11.8\%)\). A total of 838 (68.4%) participants presented with an infectious disease. The most common presenting diagnoses included bacterial pneumonia \((n = 276, 22.5\%)\), PTB \((n = 171, 14.0\%)\), acute gastroenteritis \((n = 56, 4.6\%)\), *Pneumocystis jirovecii* pneumonia \((n = 47, 3.8\%)\), cryptococcal meningitis \((n = 38, 3.1\%)\), bacterial meningitis \((n = 30, 2.5\%)\) and chronic gastroenteritis \((n = 30, 2.5\%)\).

Just over one-third presented with pathology affecting one organ system \((n = 460, 37.6\%)\) or two organ systems \((n = 432, 35.2\%)\), whilst the remainder \((n = 332, 27.2\%)\) had pathology affecting three or more organ systems.

Table 5 describes the qSOFA and NEWS-2 illness severity scores, patient disposition from the ED, length of hospital stay and in-hospital mortality of study participants. Of note, 196 (17.5%) had a high qSOFA score \(≥ 2\) points, 496 (44.4%) had a high NEWS-2 score \(≥ 7\) points, 813 (66.5%) required admission to the general ward and 205 (16.7%) required intensive care unit (ICU) admission. The median length of hospital stay was 4.9 (3.5–8.0) days, with approximately one-third \((n = 394, 32.2\%)\) requiring admission for \(≥ 7\) days. The overall mortality amongst study participants was 13.6% \((n = 166)\).

**Discussion**

To our knowledge, this is the largest single-centre study, describing the presentation of PLWH to an ED in SSA. Noteworthy findings include the large proportion of participants presenting with undiagnosed HIV, ART-treatment naïve/­non-adherence, elevated HIV VL whilst on ART, other deranged laboratory parameters, HIV-related acute illness and in-hospital mortality.

**TABLE 3:** Description of tuberculosis history and presentation among study participants.

| Variable                         | n     | %   | CD\(_4\) cell count (cells/mm\(^3\)) | HIV viral load (copies/mL) |
|----------------------------------|-------|-----|-------------------------------------|---------------------------|
|                                  |       |     | Median (IQR)                        | Median (IQR)              |
| Previous history of TB           | 294   | 24.0| 63 (26–176)                         | 97 (948, 458–657 750)     |
| TB at current presentation       | 244   | 19.9| 109 (37–296)                        | 1740 (0–240 623)          |
| First episode of TB              | 216   | 18.5| 59 (25–156)                         | 106 (823, 599–659 109)   |
| Recurrent episode of TB          | 28    | 11.5| 93 (51–252)                         | 962 (15–422 285)          |
| Single-organ TB                  | 174   | 71.3| 82 (34–226)                         | 25 (000, 248–398 515)    |
| Disseminated miliary TB          | 38    | 15.6| 37 (22–87)                          | 361 (172, 7050–1 050 000)|
| Disseminated non-miliary TB      | 32    | 13.1| 42 (14–141)                         | 157 (532, 2050–1 163 090)|
| Pulmonary TB†                    | 101   | 41.4| 89 (29–202)                         | 130 (000, 450–710 435)   |
| Extrapulmonary TB:               | 143   | 58.6| 68 (25–154)                         | 920 (468, 288 550–2 334 203)|
| Miliary TB                       | 38    | 15.6| 37 (22–87)                          | 361 (172, 7050–1 050 000)|
| Pleural TB                       | 31    | 12.7| 139 (56–313)                        | 1510 (0–69 250)           |
| Abdominal TB                     | 27    | 11.1| 54 (25–112)                         | 43 (100, 710–475 908)    |
| Tuberculous meningitis (TBM)     | 23    | 9.4 | 104 (35–220)                        | 141 (190, 231–264 500)   |
| Tuberculous lymphadenitis        | 10    | 4.1 | 21 (7–75)                           | 65 (200, 1980–1 842 000)|
| Tuberculous pericarditis         | 9     | 3.7 | 65 (47–120)                         | 3500 (819–35 963)        |
| Tuberculosis                     | 4     | 1.6 | 150 (26–269)                        | 48 (373, 15–1 005 044)   |
| Urogenital TB                    | 3     | 1.2 | 76 (39–183)                         | 210 (064, 129 459–805 032)|
| Spinal TB                        | 2     | 0.8 | 525 (512–537)                       | 2097 (1918–2275)         |
| Tuberculosis osteomyelitis       | 1     | 0.4 | 15 (15–15)                          | 531 (001, 531 001–531 001)|

Note: Probable cases of tuberculosis were also included as microbiological confirmation was not available for all cases.

TB, tuberculosis; IQR, interquartile range.

† Only includes participants with isolated pulmonary tuberculosis. The total number of pulmonary tuberculosis cases will be 171 (70.1%) if participants with both pulmonary and concurrent extrapulmonary tuberculosis are included.
During the early days of the HIV epidemic and before the introduction of highly active antiretroviral therapy, hospital admission rates amongst PLWH were substantially higher, and predominantly because of opportunistic infections and other HIV-related acute illnesses. With the widespread introduction of effective ART, the life expectancy of PLWH is approaching that of the general population, and hospital admissions in these regions have begun to reflect age-related chronic illnesses or comorbidities rather than HIV-related acute illnesses.

It is well established that the early initiation of ART and efforts to optimise ART adherence have been highly effective in curtailing the transmission of HIV and reducing HIV-associated morbidity and mortality. Hence, it is of concern that despite the free availability of ART to all South African PLWH, over two-thirds of study participants presented with opportunistic infections and other HIV-related acute illnesses. The high percentage of participants with CD4 cell counts < 100 cell/mm³ (47.6%), HIV VL > 1000 copies/mL (59.0%) and the large number of participants newly diagnosed with HIV (17.3%), or naïve to ART (24.9%) and those non-adherent to ART (32.2%) highlight the need for an urgent public health response and the implementation of innovative strategies to improve current HIV awareness and educational programmes, as well as to increase the rates of ART initiation, ART adherence and retention in care.

A previous systematic review and meta-analysis that included 313,006 pooled adult patients from 99 studies conducted in 50 countries, with studies being mostly...
conducted between 2007 and 2015 and reflecting a time when access to ART had become more widespread than before this period, reported that HIV and AIDS-related illnesses (46%) and bacterial infections (31%) were the most common reasons for hospital admission in all geographical regions. Acquired immunodeficiency syndrome-related illnesses were mostly non-bacterial opportunistic infections. Compendiary, in this study, a slightly lower proportion (68.4%) of participants presented with an infectious aetiology (bacterial and non-bacterial), fewer participants were diagnosed with HIV at presentation (17.3% vs. 30%), more were on ART (75.1% vs. 43%), the median length of hospital stay was shorter (4.3 days vs. 9 days) and in-hospital mortality was lower (13.6% vs. 20%). Despite this, the median CD₄ cell count was lower (112 cells/mm³ vs. 168 cells/mm³) in this study. Additionally, there was a higher percentage of patients in this study with bacterial pneumonia (22.5% vs. 15%) and TB (19.9% vs. 43%), whilst a lower percentage of participants were admitted with Pneumocystis jirovecii pneumonia (3.8% vs. 8%) and gastroenteritis (7.1% vs. 9%). Also, there were more cases of EPTB (58.6%) than isolated PTB (41.4%) in this study, in contrast to the pooled studies in which 67% presented with PTB. As the meta-analysis represented a wider demographic pool of patients, this may be a likely reason for the difference between findings of that study and this study.

A separate systematic review and meta-analysis consisting of 56 pooled studies conducted in SSA, which investigated trends in CD₄ cell count at presentation to a medical facility between 2002 and 2013, found that the mean estimated CD₄ cell count was 251 cells/mm³ in 2002 and 309 cells/mm³ in 2012, with no significant annual increase over the entire period. However, of the 13 studies conducted in SA, a significant increase in the CD₄ cell count of 39.9 cells per annum (p = 0.02) was noted from 2002 to 2013. The overall mean CD₄ cell count of the 13 studies conducted in SA was 257 cell/mm³, whereas in the current study this was lower (209 cell/mm³). This study is unique in that it was conducted at a tertiary-level facility, which excluded patients with low acuity conditions as they were triaged to lower-level care facilities. However, the aforementioned meta-analysis included studies conducted at ‘prevention of mother to child transmission (PMTCT)’ and other lower level of care centres, which may explain the lower mean CD₄ cell count observed in this study.

With regard to other findings of this study, anaemia in HIV-positive patients has been shown to be an independent predictor of clinical response, with a study showing that severe anaemia at baseline was associated with 13 times higher risk of death within the first year of ART initiation. Another study showed that an increasing severity of anaemia was associated with higher rates of TB and mortality, and was superior to the CD₄ cell count as a predictive marker in patients on ART.

Acute kidney injury was reported in 11.3% of study participants. Other studies reported rates of acute renal dysfunction of 2.9% – 18%, with the incidence being still high in the post-ART era. Similar to findings of this study, acute renal dysfunction has been reported more commonly in patients with a low CD₄ cell count and high HIV VL.

With regard to other significant study findings, the relatively high number of participants with an elevated CRP (84.5%), hypoalbuminemia (60.8%), hyperlactatemia (42%), thrombocytopenia (19.9%) and a high qSOFA score (17.5%) is in line with the large number of participants presenting with severe illnesses. Previous studies have shown that elevated CRP, albuminemia, hyperlactatemia, thrombocytopenia and higher qSOFA scores were predictors of mortality and poor outcomes in HIV-positive individuals.

Limitations

Limitations of this study are that this was a single-centre study, and that data were collected over a relatively short duration of 15 months. Also, with regard to the median CD₄ cell count and HIV VL values described in Tables 3 and 4, we did not account for differences between participants who were on ART and those who were not on ART or were ART non-adherent. Furthermore, as the study was conducted at a tertiary-level academic hospital and excluded patients with less severe presenting illnesses, our cumulative findings are likely to be an overestimate and not be fully reflective of the wider HIV-positive population residing within the drainage area of the hospital. A further limitation is the lack of data on chronic comorbid diseases, such as hypertension and diabetes, and the absence of follow-up outcomes post-discharge.

Conclusion

Despite the passage of more than 30 years of the HIV pandemic in Africa, PLWH are still at risk of serious morbidity and inappropriate mortality. In order to achieve
the target of ending HIV by 2030 in SA, a more urgent public health response is required. This must include more innovative strategies to improve HIV awareness, new thoughts with regard to prevention, upgrading of ART services and dedication to the retention of all PLWH in care.

Acknowledgements

The authors would like to thank the staff at the Charlotte Maxeke Johannesburg Academic Hospital for their assistance with identifying potential study participants.

Competing interests

The authors declare that they have no financial or personal relationships that may have inappropriately influenced them in writing this article.

Authors’ contributions

A.E.L. was the primary author and was responsible for the study concept, data collection, data analysis, manuscript write-up, revision and approval of the final manuscript. W.D.F.V., G.A.R. and F.P. assisted with the study design, interpretation of results, revision of the manuscript and approval of the final manuscript.

Funding information

This research was self-funded and did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.

Data availability statement

Data pertaining to this study are available from the corresponding author, A.E.L., upon request.

Disclaimer

The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the institution or funder.

References

1. UNAIDS. UNAIDS data 2020 [homepage on the Internet]. 2020 [cited 2020 Aug 21]. Available from: https://www.unaids.org/sites/default/files/media_asset/2020_aids-data-book_en.pdf
2. List of countries by HIV/AIDS adult prevalence rate [homepage on the Internet]. 2020 [cited 2020 Sep 27]. Available from: https://en.wikipedia.org/wiki/List_of_countries_by_HIV/AIDS_adult_prevalence_rate
3. Zhu H, Napravnik S, Eron JJ, et al. Decreasing excess mortality of HIV-infected patients initiating antiretroviral therapy. J Acquir Immune Defic Syndr. 2020;84(1):15–23. https://doi.org/10.1097/QAD.0b013e32836e0e0f
4. Corneli M, Grimsrud A, Faraili L, et al. Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002–2007. AIDS. 2010;24(14):2363–2370. https://doi.org/10.1097/QAD.0b013e32836d63b4
5. Jagg C, Von Overbeck J, Ledergerber B, et al. Mortality in the Swiss HIV cohort study (SHCS) and the Swiss general population. Lancet. 2003;362(9378):877–878. https://doi.org/10.1016/S0140-6736(03)14037-3
6. UNAIDS. UNAIDS Global factsheets 2020 [homepage on the Internet]. 2020 [cited 2020 Sep 28]. Available from: https://www.unaids.org/sites/default/files/media_asset/2020_aids-data-book_en.pdf
7. Mitiku K, Teklemariam Z, Weldegebreal F. Magnitude of opportunistic infections and associated factors in HIV-infected adults on antiretroviral therapy in eastern Ethiopia. HIV/AIDS – Res Palliat Care. 2015;2015:137–144. https://doi.org/10.2147/HIVS79545
8. Matoga MM, Rosenberg NE, Stanley CC, et al. Inpatient mortality rate during an era of increased access to HIV testing and ART: A cross-sectional retrospective study in Lilongwe, Malawi. PLoS One. 2018;13(2):e0191944. https://doi.org/10.1371/journal.pone.0191944
9. Bangev DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15(9):1181–1183. https://doi.org/10.1097/00002030-200106150-00015
10. Budgel EP, Maskew M, Long L, Sanne I, Fox MP. Brief report: Does most mortality in patients on ART occur in care or after lost to follow-up? Evidence from the Themba Lethu Clinic, South Africa. J Acquir Immune Defic Syndr. 2015;70(3):328–329. https://doi.org/10.1097/QAI.0000000000000755
11. Cullinan K. ARVs now for anyone with HIV – Motsosedi 2016 [homepage on the Internet]. [cited 2020 Aug 08]. Available from: https://www.health24.com/infdis/jit027
12. UNAIDS. UNAIDS data 2019 [homepage on the Internet]. 2019 [cited 2020 Sep 28]. Available from: https://data.unaids.org/publications/pdf/2019/2019-UNAIDS-data_en.pdf
13. Budd C. qSFOA. quick sepsis related organ failure assessment [homepage on the Internet]. 2016 [cited 2020 Sep 13]. Available from: https://qsofa.org/
14. National Early Warning Score (NEWS) [2] [homepage on the Internet]. 2017 [cited 2020 Sep 12]. Available from: https://www.rcplondon.ac.uk/projects/publications/national-early-warning-score-news-2
15. Mejide H, Mena A, Rodriguez-Osorio I, et al. Trends in hospital admissions, re-admissions, and in-hospital mortality among HIV-infected patients between 1993 and 2013: Impact of hepatitis C co-infection. Enferm Infecc Microbiol Clin. 2017;35(1):20–26. https://doi.org/10.1016/j.eimc.2016.07.012
16. Yang H-Y, Beymer MR, Suen S-C. Chronic disease onset among people living with HIV and AIDS in a large private insurance claims dataset. Sci Rep. 2019;9:18514. https://doi.org/10.1038/s41598-019-4596-9
17. Gakhtar K, Kamali A, Holodniy M. Health-related quality of life assessment after antiretroviral therapy: A review of the literature. Drugs. 2013;73:651–673. https://doi.org/10.1007/s11066-013-0040-4
18. Albert J, Berglund T, Gisslén M, et al. Risk of HIV transmission from patients on antiretroviral therapy. A position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy. Scand J Infect Dis. 2014;46(10):673–677. https://doi.org/10.3109/00365548.2014.926565
19. Tapson VF. Acute pulmonary embolism. N Engl J Med. 2008;358:1037–1052. https://doi.org/10.1056/NEJMra072753
20. Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis. 2002;34(8):1115–1121. https://doi.org/10.1086/339704
21. Ford N, Shubber Z, Meintjes G, et al. Causes of hospital admission among people living with HIV worldwide: A systematic review. Lancet HIV. 2015;2(10):e438–e444. https://doi.org/10.1016/S2352-3018(15)00028-X
22. Einhorn ML, Ng CK, Basset IV, Katz I, Bangsberg DR, Tsai AC. Trends in CD4 count at presentation to care and treatment initiation in sub-Saharan Africa, 2002–2013: A meta-analysis. Clin Infect Dis. 2014;60(7):1126–1127. https://doi.org/10.1093/cid/ciu1137
23. Yusuf T, Muhie OA, Shibru H. Prevalence and predictors of anemia among adult HIV infected patients at the University of Gondar Hospital, Northwest Ethiopia. HIV/AIDS – Res Palliat Care. 2019;11:211–217. https://doi.org/10.2147/HIV.529944
24. Kerkhoff AD, Wood R, Cobelens FG, Gupta-Wright A, Beker L-G, Lawn SD. The predictive value of current haemoglobin levels for incident tuberculosis and/or mortality during long-term antiretroviral therapy in South Africa: A cohort study. BMC Med. 2015;13:70. https://doi.org/10.1186/s12916-015-0320-9
25. Wyatt CM, Arons RR, Klotman PE, Klotman ME. Acute renal failure in hospitalized patients with HIV: Risk factors and impact on in-hospital mortality. Arch Intern Med. 2006;166(1):64–70. https://doi.org/10.1001/archinte.166.1.64
26. Franceschini N, Napravnik S, Eron JJ, et al. Incidence and etiology of acute renal failure among ambulatory HIV-infected patients. Kidney Int. 2006;69(7):1526–1531. https://doi.org/10.1111/j.1523-1755.2006.00232.x
27. Lopes IA, Meo MJ, Viegas A, et al. Acute kidney injury in hospitalized HIV-infected patients: A cohort analysis. Nephrol Dial Transplant. 2011;26(12):3888–3894. https://doi.org/10.1093/ndt/gfr1192
28. Lau B. C-reactive protein is a marker for human immunodeficiency virus disease progression. Arch Intern Med. 2000;160(1):64–70. https://doi.org/10.1001/archinte.160.1.64
29. Sadoff CH, Isanaka S, Aboud S, et al. Association of serum albumin concentration with mortality, morbidity, CD4 T-cell reconstitution among tanzanians initiating antiretroviral therapy. J Infect Dis. 2013;207(9):1370–1378. https://doi.org/10.1093/infdis/jit207
33. Tantisiriwat W, Tebas P, Polish LB, Casabar E, Powderly WG, Fichtenbaum CJ. Elevated lactate levels in hospitalized persons with HIV infection. AIDS Res Hum Retroviruses. 2001;17(3):195–201. https://doi.org/10.1089/088922201750063106

34. Johannessen A, Naman E, Ngowi BJ, et al. Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania. BMC Infect Dis. 2008;8:52. https://doi.org/10.1186/1471-2334-8-52

35. Maphula RW, Laher AE, Richards GA. Patterns of presentation and survival of HIV-infected patients admitted to a tertiary-level intensive care unit. HIV Med. 2020;21(5):334–341. https://doi.org/10.1111/hiv.12834

36. Aluisio AR, Garbern S, Wiskel T, et al. Mortality outcomes based on ED qSOFA score and HIV status in a developing low income country. Am J Emerg Med. 2018;36(11):2010–2019. https://doi.org/10.1016/j.ajem.2018.03.014.